Conference abstract
Genotypic diversity of human papillomavirus infection in women in Cameroon and implications for vaccination strategy
Pan African Medical Journal - Conference Proceedings. 2023:18(132).03
Oct 2023.
doi: 10.11604/pamj-cp.2023.18.132.2242
Archived on: 03 Oct 2023
Contact the corresponding author
Keywords: HR-HPV, positivity rate, genotypes, Cameroon
Oral presentation
Genotypic diversity of human papillomavirus infection in women in Cameroon and implications for vaccination strategy
Michel Carlos Tommo Tchouaket1,&, Joseph Fokam1, Samuel martin Sosso1, Ezechiel Ngoufack Jagni Semengue1, Bouba Yagai1, Rachel Kamgaing Simo1, Zacharie Sando1, Alex Durand Nka1, Gaëlle Panka Tchinda1, Désiré takou1, Nadine Fainguem1, Collins Chenwi1, Carlo-Federicco Perno2, Vittorio Colizzi3, Alexis Ndjolo1
1Chantal Biya Research Center (CIRCB), Yaoundé, Cameroon, 22Bambino Gesu Pediatric Hospital, Rome, Italy, 3University of Rome “Tor Vergata”, Rome, Italy
&Corresponding author
Introduction: high-risk human papillomavirus (HR-HPV) infections are responsible for 7.7% of cancers in developing countries, mainly cervical cancer. Several studies reveal the presence of numerous oncogenic HR-HPV genotypes worldwide, but the presence and distribution of these genotypes remain poorly known in Cameroon. The overall objective of this study was to ascertain HR-HPV genotypes circulating in Cameroon.
Methods: a cross-sectional study was conducted among non-vaccinated women in Cameroon. Detection of HR-HPV was performed by real-time PCR on cervicovaginal swabs. Predictors of HR-HPV were determined following logistic regression analysis, with p<0.05 considered statistically significant.
Results: we enrolled 364 women. The HR-HPV positivity rate was 21.43%. the positives were younger (37 [30-47] vs. 42 [34-50], P=0.002) and had a higher proportion of smokers (54.5% vs. 45.5%, P=0.005) and of those who had ≥2 sexual partners at a time in their lifetime (27.0% vs. 11.3%, P=0.001). Overall, 12 HR-HPV genotypes were identified—26.98%. As per circulating genotypes, potential vaccine effectiveness was 47% for the 4-valent and 70% for the 9-valent vaccine. Predictors of HR-HPV were young age (i.e > 41years; aOR [95%CI]: 0.408[0.194-0.862]; p=0.018); smoking (aOR: 5.199 [1.314-20.575]; p=0.018) and having >3 sex partners (aOR: 2.335[1.133-4.811]; p=0.022).
Conclusion: within the Cameroonian context, at least one out of five women is likely to be an HR-HPV carrier, especially among youth, smokers, and those with multi-sexual partners. HR-HPV infection is highly diversified, with vaccine efficacy ranging from about 47% (4-valent) to 70% (9-valent).
Genotypic diversity of human papillomavirus infection in women in Cameroon and implications for vaccination strategy
Michel Carlos Tommo Tchouaket1,&, Joseph Fokam1, Samuel martin Sosso1, Ezechiel Ngoufack Jagni Semengue1, Bouba Yagai1, Rachel Kamgaing Simo1, Zacharie Sando1, Alex Durand Nka1, Gaëlle Panka Tchinda1, Désiré takou1, Nadine Fainguem1, Collins Chenwi1, Carlo-Federicco Perno2, Vittorio Colizzi3, Alexis Ndjolo1
1Chantal Biya Research Center (CIRCB), Yaoundé, Cameroon, 22Bambino Gesu Pediatric Hospital, Rome, Italy, 3University of Rome “Tor Vergata”, Rome, Italy
&Corresponding author
Introduction: high-risk human papillomavirus (HR-HPV) infections are responsible for 7.7% of cancers in developing countries, mainly cervical cancer. Several studies reveal the presence of numerous oncogenic HR-HPV genotypes worldwide, but the presence and distribution of these genotypes remain poorly known in Cameroon. The overall objective of this study was to ascertain HR-HPV genotypes circulating in Cameroon.
Methods: a cross-sectional study was conducted among non-vaccinated women in Cameroon. Detection of HR-HPV was performed by real-time PCR on cervicovaginal swabs. Predictors of HR-HPV were determined following logistic regression analysis, with p<0.05 considered statistically significant.
Results: we enrolled 364 women. The HR-HPV positivity rate was 21.43%. the positives were younger (37 [30-47] vs. 42 [34-50], P=0.002) and had a higher proportion of smokers (54.5% vs. 45.5%, P=0.005) and of those who had ≥2 sexual partners at a time in their lifetime (27.0% vs. 11.3%, P=0.001). Overall, 12 HR-HPV genotypes were identified—26.98%. As per circulating genotypes, potential vaccine effectiveness was 47% for the 4-valent and 70% for the 9-valent vaccine. Predictors of HR-HPV were young age (i.e > 41years; aOR [95%CI]: 0.408[0.194-0.862]; p=0.018); smoking (aOR: 5.199 [1.314-20.575]; p=0.018) and having >3 sex partners (aOR: 2.335[1.133-4.811]; p=0.022).
Conclusion: within the Cameroonian context, at least one out of five women is likely to be an HR-HPV carrier, especially among youth, smokers, and those with multi-sexual partners. HR-HPV infection is highly diversified, with vaccine efficacy ranging from about 47% (4-valent) to 70% (9-valent).
